MX340626B - Levoisovalerilespiramicina i, ii, iii y preparaciones, métodos de preparación y sus usos. - Google Patents
Levoisovalerilespiramicina i, ii, iii y preparaciones, métodos de preparación y sus usos.Info
- Publication number
- MX340626B MX340626B MX2012013470A MX2012013470A MX340626B MX 340626 B MX340626 B MX 340626B MX 2012013470 A MX2012013470 A MX 2012013470A MX 2012013470 A MX2012013470 A MX 2012013470A MX 340626 B MX340626 B MX 340626B
- Authority
- MX
- Mexico
- Prior art keywords
- levoisovalerylspiramycin
- iii
- preparations
- preparation methods
- injection
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 6
- 238000002347 injection Methods 0.000 abstract 2
- 239000007924 injection Substances 0.000 abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000008176 lyophilized powder Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/44—Preparation of O-glycosides, e.g. glucosides
- C12P19/60—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
- C12P19/62—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin the hetero ring having eight or more ring members and only oxygen as ring hetero atoms, e.g. erythromycin, spiramycin, nystatin
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Se describen la levoisovalerilespiramicina I,II o III, preparaciones, métodos de preparación y sus usos. Las preparaciones comprenden levoisovalerilespiramicina I, II,o III y vehiculo fasrmaceuticamente aceptable y/o adyuvante, en donde la pureza de levoisovalerilesparamicina I, II, III está por encima de 90% en peso. La de levoisovalerilesparamicina I, II o III tiene una buena actividad antibacteriana, y las preparaciones incluyen soluciones para inyección. Polvo para inyección o polvo liofilizado para inyección.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010182111 | 2010-05-25 | ||
| CN201010182108 | 2010-05-25 | ||
| CN201010182109 | 2010-05-25 | ||
| PCT/CN2011/074644 WO2011147313A1 (zh) | 2010-05-25 | 2011-05-25 | 左旋异戊酰螺旋霉素i、ii或iii，及其制剂、制备方法及应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012013470A MX2012013470A (es) | 2013-03-18 |
| MX340626B true MX340626B (es) | 2016-07-18 |
Family
ID=45003321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012013470A MX340626B (es) | 2010-05-25 | 2011-05-25 | Levoisovalerilespiramicina i, ii, iii y preparaciones, métodos de preparación y sus usos. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8778896B2 (es) |
| EP (3) | EP3210991B1 (es) |
| JP (1) | JP5945868B2 (es) |
| KR (2) | KR101706518B1 (es) |
| BR (1) | BR112012029913B1 (es) |
| CA (3) | CA2800021C (es) |
| DK (3) | DK2578595T3 (es) |
| ES (3) | ES2754614T3 (es) |
| MX (1) | MX340626B (es) |
| MY (1) | MY164231A (es) |
| PL (3) | PL3210990T3 (es) |
| PT (1) | PT3210990T (es) |
| RU (3) | RU2647237C1 (es) |
| WO (1) | WO2011147313A1 (es) |
| ZA (3) | ZA201209738B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2800019C (en) * | 2010-05-25 | 2015-05-26 | Shenyang Tonglian Group Co., Ltd. | Levocarrimycin, pharmaceutical compositions, preparation methods and uses thereof |
| CN105497053B (zh) * | 2015-12-31 | 2018-02-13 | 沈阳福洋医药科技有限公司 | 可利霉素在抗结核分枝杆菌感染中的应用 |
| ES2912734T3 (es) * | 2017-07-04 | 2022-05-27 | Shenyang Fuyang Pharmaceutical Tech Co Ltd | Uso de isovaleril espiramicina I o III en la preparación de fármaco para tratar y/o prevenir el tumor y fármaco |
| RU2768583C2 (ru) * | 2018-01-19 | 2022-03-24 | Шенянг Фуянг Фармасьютекал Технолоджи Ко., Лтд. | Ингибитор мишени рапамицина в клетках млекопитающих, фармацевтическая композиция и их применение |
| KR20200112898A (ko) | 2018-01-19 | 2020-10-05 | 쉔양 푸양 파마슈티컬 테크놀로지 컴퍼니 리미티드 | 캐리마이신 또는 이의 활성 성분의 용도 |
| CN110384710B (zh) * | 2018-04-17 | 2023-01-10 | 沈阳福洋医药科技有限公司 | 一种用于预防和/或治疗疼痛的药物、组合产品及其应用 |
| US20210177881A1 (en) * | 2018-04-17 | 2021-06-17 | Shanghai Tonglian Pharmaceutical Co., Ltd. | Medicament for preventing and/or treating pain and/or fever, composite product and use thereof |
| EP3970728A4 (en) * | 2019-05-16 | 2022-07-27 | Shenyang Fuyang Pharmaceutical Technology Co., Ltd. | MEDICINE AND COMBINATION PRODUCT USED FOR THE PREVENTION, RELIEF AND/OR TREATMENT OF FIBROSIS AND USE OF IT |
| CN112239483B (zh) * | 2019-07-18 | 2023-10-27 | 沈阳福洋医药科技有限公司 | 一种化合物及药物组合物 |
| US11351185B2 (en) | 2020-03-11 | 2022-06-07 | Asclea Corporation | Use of isovalerylspiramycins as anti-cancer agents to inhibit metastasis |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5334788A (en) * | 1976-09-11 | 1978-03-31 | Sanraku Inc | Antibiotics spiramycin derivatives |
| CN1058295C (zh) | 1997-06-03 | 2000-11-08 | 中国医学科学院医药生物技术研究所 | 一种利用基因工程技术制造生技霉素的方法 |
| CN1169947C (zh) * | 2002-11-19 | 2004-10-06 | 中国医学科学院医药生物技术研究所 | 必特螺旋霉素的基因工程菌株螺旋霉素链霉菌wsj-195 |
| CN1237976C (zh) * | 2003-12-23 | 2006-01-25 | 沈阳同联集团有限公司 | 必特螺旋霉素及其在抗感染性疾病中的应用 |
| CA2576291A1 (en) * | 2004-08-12 | 2006-02-23 | Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. | Use of cell-specific conjugates for treatment of inflammatory diseases of the gastrointestinal tract |
| CN101054553A (zh) * | 2007-04-09 | 2007-10-17 | 中国医学科学院医药生物技术研究所 | 异戊酰螺旋霉素i基因工程菌株的构建 |
| CN101649325B (zh) * | 2009-07-03 | 2011-09-07 | 中国医学科学院医药生物技术研究所 | 一种提高基因工程异戊酰螺旋霉素主组分含量的基因串连技术 |
| CN101773510B (zh) * | 2010-03-09 | 2013-06-05 | 沈阳同联集团有限公司 | 异戊酰螺旋霉素iii的分离制备 |
| CN101785779B (zh) * | 2010-03-09 | 2014-03-05 | 沈阳同联集团有限公司 | 异戊酰螺旋霉素ii的分离制备 |
| CN101785778A (zh) | 2010-03-09 | 2010-07-28 | 沈阳同联集团有限公司 | 异戊酰螺旋霉素i的分离制备及其应用 |
| CA2800019C (en) * | 2010-05-25 | 2015-05-26 | Shenyang Tonglian Group Co., Ltd. | Levocarrimycin, pharmaceutical compositions, preparation methods and uses thereof |
-
2011
- 2011-05-25 PL PL17166117T patent/PL3210990T3/pl unknown
- 2011-05-25 EP EP17166118.4A patent/EP3210991B1/en active Active
- 2011-05-25 ES ES17166118T patent/ES2754614T3/es active Active
- 2011-05-25 KR KR1020167002374A patent/KR101706518B1/ko active IP Right Grant
- 2011-05-25 PL PL17166118T patent/PL3210991T3/pl unknown
- 2011-05-25 DK DK11786085.8T patent/DK2578595T3/en active
- 2011-05-25 RU RU2016123980A patent/RU2647237C1/ru active IP Right Revival
- 2011-05-25 JP JP2013511523A patent/JP5945868B2/ja active Active
- 2011-05-25 DK DK17166117.6T patent/DK3210990T3/da active
- 2011-05-25 CA CA2800021A patent/CA2800021C/en active Active
- 2011-05-25 WO PCT/CN2011/074644 patent/WO2011147313A1/zh active Application Filing
- 2011-05-25 DK DK17166118T patent/DK3210991T3/da active
- 2011-05-25 US US13/699,459 patent/US8778896B2/en active Active
- 2011-05-25 ES ES17166117T patent/ES2781425T3/es active Active
- 2011-05-25 RU RU2012156420/04A patent/RU2593498C2/ru active IP Right Revival
- 2011-05-25 CA CA2915236A patent/CA2915236C/en active Active
- 2011-05-25 PL PL11786085T patent/PL2578595T3/pl unknown
- 2011-05-25 MY MYPI2012700969A patent/MY164231A/en unknown
- 2011-05-25 KR KR1020127033721A patent/KR20130041829A/ko active Application Filing
- 2011-05-25 EP EP11786085.8A patent/EP2578595B1/en active Active
- 2011-05-25 ES ES11786085.8T patent/ES2633723T3/es active Active
- 2011-05-25 PT PT171661176T patent/PT3210990T/pt unknown
- 2011-05-25 RU RU2016123979A patent/RU2647236C1/ru active IP Right Revival
- 2011-05-25 BR BR112012029913-1A patent/BR112012029913B1/pt not_active IP Right Cessation
- 2011-05-25 EP EP17166117.6A patent/EP3210990B1/en active Active
- 2011-05-25 CA CA2915222A patent/CA2915222C/en active Active
- 2011-05-25 MX MX2012013470A patent/MX340626B/es active IP Right Grant
-
2012
- 2012-12-21 ZA ZA2012/09738A patent/ZA201209738B/en unknown
-
2014
- 2014-08-29 ZA ZA2014/06381A patent/ZA201406381B/en unknown
- 2014-08-29 ZA ZA2014/06382A patent/ZA201406382B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX340626B (es) | Levoisovalerilespiramicina i, ii, iii y preparaciones, métodos de preparación y sus usos. | |
| WO2014205317A3 (en) | Cyclic peptides as protein targeting agents | |
| MX2010005889A (es) | Derivados de tiofeno como agonistas de s1p1/edg1. | |
| NZ622566A (en) | Chromobacterium bioactive compositions and metabolites | |
| MY188960A (en) | Cyclic boronic acid ester derivatives and therapeutic uses thereof | |
| NZ602328A (en) | Novel compounds and compositions for targeting cancer stem cells | |
| MX348823B (es) | Formulaciones estables de linaclotida. | |
| MX2013007104A (es) | Derivados de biciclo[3,2,1]octilamida y sus usos. | |
| WO2015019198A3 (en) | High potency pancreatin pharmaceutical compositions | |
| MX347734B (es) | Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas. | |
| TW200942530A (en) | Pyridine compounds | |
| NZ708016A (en) | Lyophilized preparations of melphalan flufenamide | |
| WO2012066488A3 (en) | Bridged spiro[2.4]heptane ester derivatives | |
| UA111599C2 (uk) | Композиція каспофунгіну | |
| MX2013006418A (es) | Derivados de oxazolil-metileter como agonistas del receptor de alx. | |
| NZ594019A (en) | Novel antibacterial agents for the treatment of gram positive infections | |
| TN2015000090A1 (en) | Daptomycin formulations and uses thereof | |
| PH12014502465A1 (en) | Fluorinated bridged spiro[2.4]heptane derivatives as alx receptor agonists | |
| MX2012007590A (es) | Composicion para mejorar la funcion cerebral y metodo para mejorar la funcion cerebral. | |
| MX2012007896A (es) | Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica. | |
| WO2014062838A3 (en) | Pkm2 modulators and methods for their use | |
| MX2011010359A (es) | Composición de 2,4,6-trifluoro-n-[6-(1-metilo-piperidina-4-carboni lo)-piridina-2-ilo]-benzamida. | |
| TN2012000105A1 (en) | Spirolactam derivatives and uses of same | |
| MX344189B (es) | Formulaciones de mazindol. | |
| WO2013106756A3 (en) | Antimicrobial agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |